Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2010 – December 31, 2010 Compiled by Lynn Day, RN BSN CCM CCRP.

Slides:

Advertisements

Similar presentations

Mammary ductal carcinoma

Advertisements

Evidence for adjuvant radiation therapy benefiting breast cancer patients with 1 to 3 positive lymph nodes treated with a modified radical mastectomy and.

Baptist Health System General Surgery Residency Program

Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.

Pimp Session: Breast By James Lee, MD.

Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Breast Cancer in Pregnancy

An update for Illinois Nurses Elizabeth A. Peralta, MD The Breast Center at SIU Springfield, IL May 2011.

Christine Simmons, MD MSc FRCPC Medical Oncologist, BCCA Vancouver

The Call (a brief tour of breast cancer) Family Medicine Review Course 2011 Christian Cable, MD, FACP.

Breast Reconstruction: Outcomes Analysis Michael J Bass, MD, JD Michael J Bass Plastic Surgery, PLLC.

Breast Cancer Tumor Board Chair Harold Burstein, MD, PhD Faculty Jennifer Bellon, MD Mehra Golshan, MD.

Sentinel Lymph Node Dissection (SND)

What is cancer? A cancer is a malignant tumor, which are cells that multiply out of control, destroying healthy tissues (Dictionary)

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

AJCC TNM Staging 7th Edition Breast Case #3

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.

Ductal Carcinoma in situ

Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.

AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.

SURGEONS ROLE AND INVOLVEMENT IN SBRT PROGRAM Stephen R. Hazelrigg, M.D. Professor and Chair, Cardiothoracic Surgery Southern Illinois University, School.

Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA

Maximally-Invasive Curriculum: A Model Curriculum for Osteopathic Surgical Residencies (ACOS) India Broyles, EdD University of New England College of Osteopathic.

Nurse Navigators and the Cancer Institute Yousuf A. Gaffar, MD Hematology / Medical Oncology The Cancer Institute University of Maryland St. Joseph Medical.

Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.

Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.

AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.

Breast Carcinoma. Anatomy Epidemiology: 10% 17.1/10 28/10 46/ m world wide 6% develop cancer of the breast in their lifetime. 50,000 to 70,000.

Breast Cancer Methods for Early Detection. Breast Cancer What It Is Methods of Early Detection Risk Factors.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

NYU Medical Grand Rounds Clinical Vignette Daniel P. Eiras, MD, MPH PGY2 December 1, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2013 – December 31, 2013 Compiled by Uzma Nazim, M.D.

CBACT: Cost Benefit Analysis for Cancer Treatments Adeeti Aggarwal Saratoga High School February 20, 2009.

2014 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013.

NYU Medical Grand Rounds Clinical Vignette Denise Pate MD, PGY-2 January 27, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

Radical Mastectomy is no longer the standard Improved adjuvant and neoadjuvant therapy Chemotherapy Endocrine therapy Radiation treatment Reconstruction.

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.

MBCG Project Primary Results MEDICALSURVEYS-17 RESEARCH GROUP IN COLLABORATION WITH THE EASO.

Recent and evolving trends in breast and colon cancer by Jeff Kolbasnik.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2014 – December 31, 2014 Compiled by L.Day, RN BSN CCM CCRP OCN 1.

Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2009 – December 31, 2009.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2011 – December 31, 2011 Compiled by Lynn Day, RN BSN CCM CCRP.

2015 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2012 – December 31, 2012 Compiled by Uzma Nazim, M.D.

Extranodal Extension on Sentinel Lymph Node Dissection: Why Should We Treat It Differently? Audrey Choi MD, Matthew Surrusco MD, Samuel Rodriguez MD, Khaled.

SLNB Scenario Group Discussion Presented at: The Sentinel Lymph Node Biopsy Surgery Refresher Course October 29, 2010.

Breast Cancer 1. Leukemia & Lymphoma New diagnoses each year in the US: 112, 610 Adults 5,720 Children 43,340 died of leukemia or lymphoma in

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee.

Presented at the NAACCR Annual Conference Quebec City June 22, 2010.

Ontario SLNB Quality Data: A Provincial Snapshot May Lynn Quan MD, MSc, FRCSC 1 Why it matters to YOU!

ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Harvard Medical School Date 06/01/2007.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

The POSITIVE study A large international research effort coordinated by International Breast Cancer Study Group (IBCSG) worldwide ALLIANCE for Clinical.

BREAST CANCER ONCOLOGY NAVIGATION SERVICE

Coordination (benign lesions)

THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.

Thanh Nhan Hospital MALE BREAST CANCER: CASE REPORT

Treatment Overview: The Multidisciplinary Team

Lung Cancer Screening Sandra Starnes, MD Professor of Surgery

Early and locally advanced breast cancer

Presentation transcript:

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2010 – December 31, 2010 Compiled by Lynn Day, RN BSN CCM CCRP

Stage Distribution Total Number of Patients = 121 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun7 (10.94%) 25 (39.06%) 13 (20.31%) 8 (12.5%) 0 (0%) 11 (17.19%) 64 (100%) Jul - Dec10 (17.54%) 22 (38.6%) 13 (22.8%) 3 (5.26%) 0 (0%) 9 (15.79%) 57 (100%) Jan-Dec17 (14.05%) 47 (38.84%) 26 (21.48%) 11 (9.09%) 0 (0%) 20 (16.53%) 121 (100%) Compiled by Lynn Day, RN BSN CCM CCRP

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Preoperative Core 12 (18.75%) 27 (42.19%) 14 (21.87%) 8 (12.5%) 0 (0%) 3 (4.69%) 64 (100%) Jul – Dec Preoperative Core 12 (21.05%) 23 (40.35%) 15 (26.31%) 3 (5.26%) 0 (0%) 2 (3.51%) 55 (96.49%) Jan-Dec Preoperative Core 24 (19.83%) 50 (41.32%) 29 (23.96%) 11 (9.09%) 0 (0%) 5 (4.13%) 119 (98.35%) Mode of Diagnosis Total Number of Patients = % of patients had diagnosis established on preoperative core needle biopsy Exceptions – excisional biopsy by other MD and shave biopsy Compiled by Lynn Day, RN BSN CCM CCRP

Tumor Board Discussion Total Number of Patients = 121 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Discussed 7/12 (58.33%) 4/27 (14.81%) 8/14 (57.14) 4/8 (50%) 0 (0%) 0/3 (0%) 23/64 (35.94%) Jul – Dec Discussed 5/12 (41.66%) 8/24 (33.33%) 6/15 (40%) 2/4 (50%) 0 (0%) 0/2 (0%) 40/57 (75.47%) Jan-Dec Discussed 12/24 (50.0%) 12/51 (23.53%) 14/29 (48.28) 6/12 (50%) 0 (0%) 0/5 (0%) 44/121 (36.36%) 36.36% of patients were discussed prospectively in the multidisciplinary tumor conference 14.05% of patients were discussed retrospectively in the multidisciplinary tumor conference Compiled by Lynn Day, RN BSN CCM CCRP

Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun MDC seen 9/12 (75%) 24/27 (88.89%) 10/14 (71.43%) 8/8 (100%) 0 (0%) 1/3 (33.33%) 52/64 (81.25%) Jul – Dec MDC seen 10/12 (83.33%) 21/24 (87.5%) 12/15 (80%) 3/4 (75%) 0 (0%) 1/2 (50.0%) 47/57 (82.46%) Jan-Dec MDC seen 19/24 (79.17%) 45/51 (88.24%) 22/29 (75.86%) 11/12 (91.67%) 0 (0%) 2/5 (40%) 82/121 (67.77%) Multidisciplinary Assessment (Surgical, Medical and Radiation Oncologist) Total Number of Patients = 121 Exceptions22/121 (18.18%) No radiation oncology evaluation (mast./ high-risk) 9/22 (40.9%) No documentation in the chart 8/22 (36.36%) Patient non-compliance 2/22 (9.09%) Continuing chemotherapy 1/22 (4.55%) Deceased during treatment 2/22 (9.09%) Compiled by Lynn Day, RN BSN CCM CCRP

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Assigned 11/12 (91.67%) 27/27 (100%) 14/14 (100%) 8/8 (100%) 0 (0%) 3/3 (100%) 63/64 (98.44%) Jul – Dec Assigned 12/12 (100%) 23/24 (95.83%) 15/15 (100%) 4/4 (100%) 0 (0%) 1/2 (50%) 55/57 (96.49%) Jan-Dec Assigned 23/24 (95.83%) 50/51 (98.04%) 29/29 (100%) 12/12 (100%) 0 (0%) 4/5 (80%) 118/121 (97.52%) Nurse Navigation Total Number of Patients = 121 Exceptions3/121 (2.48%) Lateral entry into the system1/3 (33.33%)* Patient moved care 2/3 (66.67%) *modifications made to ensure assignment of a nurse navigator for every patient Compiled by Lynn Day, RN BSN CCM CCRP

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Yes 4/12 (33.33%) 27/27 (100%) 14/14 (100%) 8/8 (100%) 0 (0%) 0/3 (0%) 53/64 (82.81%) Jul – Dec Yes 1/12 (8.33%) 24/24 (100%) 15/15 (100%) 4/4 (100%) 0 (0%) 0/2 (0%) 44/57 (71.19%) Jan-Dec Yes 5/24 (20.83%) 51/51 (100%) 29/29 (100%) 12/12 (100%) 0/0 (0%) 0/5 (0%) 97/121 (80.17%) CAP Compliance Total Number of Patients = 121 Exceptions24/121(19.83%) Progesterone receptor not reported (DCIS)13/24 (54.17%) Complete response, no margins 6/24 (25%) Final surgery not done 4/24 (16.67%) Patient non-compliance, no follow up, moved 1/24 (4.17 %) Compiled by Lynn Day, RN BSN CCM CCRP

Axillary Staging Total Number of Patients = 121 Total Number of Patients with Invasive Cancer = 97 Number node positive patients on needle biopsy15/97 (15.47%) Number of patients eligible for SLNB85/97 (87.62%) – Number of patients with SLNB69/97 (71.13%) Exceptions16/97 (16.49%) Determined low risk (unlikely to change treatment plan)11/16 (68.75%) Final surgery not done 1/16 (6.25%) Patient non-compliance, no follow up, moved4/16 (25%) Compiled by Lynn Day, RN BSN CCM CCRP

Axillary Dissection Total Number of Patients = 121 Total Number of Patients with Invasive Cancer = 97 Number of Patients with node positive disease 34/97 (35.05%) Number of patients eligible for ALND 34 – Number of patients with ALND 25/34 (73.52) Exceptions9/34 (26.47%) Low risk for non-SLN mets. on MSKCC nomogram5/34 (14.7%) Final surgery not done 1/34 (2.94%) Patient refused completion ALND0/34 (0%) Patient high risk for completion ALND3/34 (8.82%) Compiled by Lynn Day, RN BSN CCM CCRP

Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Yes 9/12 (75%) 27/27 (100%) 7/14 (50%) 4/8 (50%) 0 (0%) 0/3 (0%) 47/64 (73.44%) Jul – Dec Yes 7/12 (58.33%) 18/24 (75%) 6/15 (40%) 0/4 (0%) 0 (0%) 0/2 (0%) 31/57 (54.4%) Jan-Dec Yes 16/24 (66.67%) 45/51 (88.24%) 13/29 (44.83%) 4/12 (33.33%) 0 (0%) 0/5 (0%) 78/121 (64.46%) Breast Conservation Total Number of Patients = 121 Number of early stage patients (0, I and II) with breast conservation 74/104 (71.15%) Compiled by Lynn Day, RN BSN CCM CCRP

Post-lumpectomy Radiation Total Number of Patients = 121 Number of patients with lumpectomy78/121 (64.46%) Number of patients eligible for Radiation78 – Number of patients radiated72/78 (92.3%) Exceptions6/78 (7.69%) Low risk malignancy age group 75 – 93 years1/6 (16.67%) severe co morbidities Progressed to mastectomy2/6 (33.33%) Patient non-compliance/moved2/6 (33.33%) History of past radiation1/6 (16.67%) Number of patients radiated within 12 months72/78 (92.3%) Compiled by Lynn Day, RN BSN CCM CCRP

Post-Mastectomy Radiation Total Number of Patients = 121 Number of patients with mastectomy38/121 (31.4%) Number eligible for radiation (>T3 or >N2)9/38 (23.68%) – Number of patients radiated7/9 (77.78%) Exceptions2/9 (22.22%) - History of prior radiation1/2 (50%) - Patient non-compliance 1/2 (50%) Number of patients radiated within 12 months5/9 (55.56%) Compiled by Lynn Day, RN BSN CCM CCRP

Systemic Chemotherapy - I Total Number of Patients = 121  ER negative patients with cancer18/121 (14.88%) Number eligible for chemotherapy(exclude DCIS)14/18 (77.78%) – Number treated with chemotherapy9/14 (64.29%) Exceptions5/14 (35.71%) Patient refused chemo2/5 (40%) Patient moved care1/5 (20%) Chemo not recommended2/5 (40%)  Number with chemotherapy within 4 months9/9 (100%) Exceptions0 (none) Patient non-compliance 0 (none) Compiled by Lynn Day, RN BSN CCM CCRP

Systemic Chemotherapy - II Total Number of Patients = 121  ER positive patients with cancer103/121 (85.12%) Number eligible for chemotherapy (exclude DCIS)83/103 (81.9%) Number treated with chemotherapy41/83 (49.41%)  Number with chemotherapy within 4 months39/41 (95.12%) Exceptions2/41 (4.88%) Patient initiated treatment delay2/2 (100%) (1 stage II, 1 stage III) Compiled by Lynn Day, RN BSN CCM CCRP

Systemic Endocrine Therapy Total Number of Patients = 121  Number of ER positive patients103/121 (85.12%) Number treated with endocrine therapy93/103 (90.29%) Exceptions10/103 (9.71%) Determined risk > benefit 5/10 (50%) Patient deceased during treatment 1/10 (10%) Patient non-compliance 4/10 (40%)  Number with endocrine therapy within 1 year90/93 (96.77%) Compiled by Lynn Day, RN BSN CCM CCRP

Rehabilitation Total Number of Patients = 121 Number enrolled in CPRP (PT/OT)36/121 (29.75%) Exceptions85/121 (70.25%) Services were available but structured program was recently established, whereby every patient gets a baseline exam documented; prospective data is maintained with a pre-designed schedule. Improvement over % Compiled by Lynn Day, RN BSN CCM CCRP

Genetic Counseling Total Number of Patients = 121 Number of patients with family history or < 45 years75/121 (61.98%) Number received genetic counseling37/75 (49.33%) – Number tested20/37 (54.05%) Positive 5/20 (25%) Negative15/20 (75%) – Number refused testing22/37 (59.46%) Exceptions37/75 (49.33%) Did not meet NCCN criteria24/37 (64.86%) No documentation in the chart13/37 (35.14%) Patient deceased during treatment1/37 (2.70%) Compiled by Lynn Day, RN BSN CCM CCRP

Time Frame Trial / StudyEligible N (%) Participation N (%) Jan – Jun B-SMART13 (20.64%)12 (19.05%) SPOC22 (34.92%) Total 35 (55.56%)34 (53.97%) Jul - Dec B-SMART16 (27.59%) SPOC45 (77.59%) Total 47 (81.03%) Trial Participation Total Number of Patients = 121 Total Number of patients enrolled in trials in /121 (64.46%) Increase of patients enrolled over the year /15 (520%) Compiled by Lynn Day, RN BSN CCM CCRP